Clinical trial
Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
NCT00143572 · St. Jude Children's Research Hospital, Other · Completed
Key facts
| NCT number | NCT00143572 |
|---|---|
| Title | Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease |
| Official title | Phase I Study of Combination Treatment With Hydroxyurea and Magnesium Pidolate in Patients With Sickle Cell Disease |
| Lead sponsor | St. Jude Children's Research Hospital, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Anemia, Sickle Cell |
| Intervention type | Drug |
| Interventions | Magnesium Pidolate, Hydroxyurea |
| Enrollment | 16 |
| Start date | Nov 1, 2004 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Sep 2, 2005 |
| Last update posted | Apr 26, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: